Диссертация (1140954), страница 13
Текст из файла (страница 13)
– P. 1.49.Dubrovska A. CXCR4 expression in prostate cancer progenitor cells / A.Dubrovska, J. Elliott, R.J. Salamone, G.D. Telegeev, A.E. Stakhovsky et al. //PloS one. – 2012. – V. 7(2). – P. e31226.50.Eisenhardt A. Expression analysis and potential functional role of the CXCR4chemokine receptor in bladder cancer / A. Eisenhardt, U. Frey, M. Tack, D.Rosskopf, G. Lummen, H. Rubben, W. Siffert // Eur. Urol. – 2005. – V. 47(1). –P.
111–117.51.Engl T. CXCR4 chemokine receptor mediates prostate tumor cell adhesionthrough alpha5 and beta3 integrins / T. Engl, B. Relja, D. Marian, C. Blumenberg,I. Muller et al. // Neoplasia. – 2006. – V. 8(4). – P. 290–301.52.Fabbri M. MicroRNAs bind to Toll-like receptors to induce prometastaticinflammatory response / M. Fabbri et al. // Proc Natl Acad Sci U S A.
– 2012. –V. 109. – P. E2110–2116.8753.Facciabene A. Tumour hypoxia promotes tolerance and angiogenesis via CCL28and Treg cells / A. Facciabene, X. Peng, I.S. Hagemann, K. Balint, A. Barchetti,L-P. Wang et al. // Nature. – 2011. – V. 475. – P. 226–30.54.Forte G. Polyinosinic-polycytidylic acid limits tumor outgrowth in a mousemodel of metastatic lung cancer / G. Forte et al. // J Immunol. – 2012. – V. 188.
–P. 5357–5364.55.Franco R. CXCR4-CXCL12 and VEGF correlate to uveal melanoma progression/ R. Franco, G. Botti, M. Mascolo, G. Loquercio, G. Liguori et al. // Front Biosci(Elite Ed). – 2010. – V. 2. – P. 13–21.56.Fukata M. Toll-like receptor-4 promotes the development of colitis-associatedcolorectal tumors / M.
Fukata et al. // Gastroenterology. – 2007. – V.133. – P.1869–1881.57.Furusato B. CXCR4 and cancer / B. Furusato, A. Mohamed, M. Uhlen, J.S. Rhim// Pathol. Int. – 2010. – V. 60(7). – P. 497–505.58.Galluzzi L. Trial Watch: Experimental Toll-like receptor agonists for cancertherapy / L. Galluzzi et al. //Oncoimmunology. – 2012. – V. 1.
– P. 699–716.59.Garaude J. Simultaneous targeting of toll- and nod-like receptors induceseffective tumor-specific immune responses / J. Garaude, A. Kent, N. van Rooijen,J.M. Blander // Science translational medicine. – 2012. – V.4. – P. 12060.Gibson S.J. Plasmacytoid dendritic cells produce cytokines and mature inresponse to the TLR7 agonists, imiquimod and resiquimod / S.J. Gibson et al. //Cellular immunology. – 2002. – V. 218. – P.
74–86.61.Gill S.S. Small intestinal neoplasms / S.S. Gill, D.M. Heuman, A.A. Mihas // J.Clin. Gastroenterol. – 2001. – V. 33(4). – P. 267–282.62.Gilmore T.D. The Rel/NF-kappaB signal transduction pathway: introduction /T.D. Gilmore // Oncogene. – 1999. – V. 18. – P. 6842–6844.63.Goldszmid RS, Trinchieri G. The price of immunity // Nat Immunol. – 2012 –V.13 – P. 932–938.8864.González-Martín A. Maximal T cell-mediated antitumor responses rely uponCCR5 expression in both CD4+ and CD8+ T cells / A. González-Martín, L.Gómez, J. Lustgarten, E. Mira, S. Mañes // Cancer Res.
– 2011. – V. 71. – P.5455–5466.65.Goutagny N. Targeting pattern recognition receptors in cancer immunotherapy /N. Goutagny, Y. Estornes, U. Hasan, S. Lebecque, C. Caux // Targeted oncology.– 2012. – V. 7. – P. 29–54.66.Grivennikov S.I. Immunity, inflammation, and cancer / S.I. Grivennikov, F.R.Greten, M. Karin // Cell. – 2010. – V. 140(6). – P. 883–899.67.Groom J.R. CXCR3 in T cell function / J.R. Groom, A.D.
Luster // Exp Cell Res.– 2011. – V. 317. – P. 620–631.68.Hanahan D. Hallmarks of cancer: the next generation / D. Hanahan, R.Weinberg// Cell. – 2011. – V. 144. – P. 646–674.69.Harris N.L. A revised European-American classification of lymphoid neoplasms:a proposal from the International Lymphoma Study Group / N.L. Harris, E.S.Jaffe, H. Stein, P.M. Banks, J.K.
Chan et al. // Blood. – 1994. – V. 84(5). – P.1361–1392.70.Hasan U.A. Cell proliferation and survival induced by Toll-like receptors isantagonized by type I IFNs / U.A. Hasan et al. // Proc Natl Acad Sci U S A. –2007. – V. 104. – P. 8047–8052.71.Hartmann G. CpG DNA: a potent signal for growth, activation, and maturation ofhuman dendritic cells / G.
Hartmann, G.J. Weiner, A.M. Krieg // Proc Natl AcadSci U S A. – 1999. – V. 96. – P. 9305–9310.72.Heckelsmiller K. Peritumoral CpG DNA elicits a coordinated response of CD8 Tcells and innate effectors to cure established tumors in a murine colon carcinomamodel / K. Heckelsmiller et al. // Journal of immunology (Baltimore, Md: 1950).– 2002. – V. 169. – P. 3892–3899.8973.Hemmi H. Small anti-viral compounds activate immune cells via the TLR7MyD88-dependent signaling pathway / H.
Hemmi et al. // Nat Immunol. – 2002.– V. 3. – P. 196–200.74.Hennessy E.J. Targeting Toll-like receptors: emerging therapeutics? / E.J.Hennessy, A.E. Parker, L.A. O’Neill // Nat Rev Drug Discov. – 2010. – V. 9. – P.293–307.75.Hensbergen P.J. The CXCR3 targeting chemokine CXCL11 has potent antitumoractivity in vivo involving attraction of CD8+ T lymphocytes but not inhibition ofangiogenesis / P.J.
Hensbergen, P.G.B. Wijnands, M.W. Schreurs, R.J. Scheper,R. Willemze, C.P. Tensen // J Immunother. – 2005. – V. 28. – P. 343–351.76.Hoerning A. Subsets of human CD4+ regulatory T cells express the peripheralhoming receptor CXCR3 / A. Hoerning, K. Koss, D. Datta, L. Boneschansker,C.N. Jones, I.Y. Wong et al. // Eur J Immunol. – 2011.
– V. 41. – P. 2291–2302.77.HomeyB.CCL27-CCR10interactionsregulateTcell-mediatedskininflammation / B. Homey, H. Alenius, A. Muller, H. Soto, E.P. Bowman et al. //Nat. Med. – 2002. – V. 8(2). – P. 157–165.78.Huang B. Toll-like receptors on tumor cells facilitate evasion of immunesurveillance / B. Huang et al.
// Cancer research. – 2005. – V. 65. – P. 5009–5014.79.Ignatz-Hoover J.J. The role of TLR8 signaling in acute myeloid leukemiadifferentiation / J.J. Ignatz-Hoover, H. Wang, S.A. Moreton, A. Chakrabarti,M.K. Agarwal et al. // Leukemia. – 2015. – V. 29(4). – P. 918–926.80.Izhak L. Dissecting the autocrine and paracrine roles of the CCR2-CCL2 axis intumor survival and angiogenesis / L. Izhak, G. Wildbaum, S. Jung, A.
Stein, Y.Shaked, N. Karin // PloS one. – 2012. – V. 7(1). – P. e28305.81.Je E.M. Absence of MYD88 gene mutation in acute leukemias and multiplemyelomas / E.M. Je, N.J. Yoo, S.H. Lee // Eur J Haematol. – 2012. – V. 88 (3). –P. 273–2749082.Jemal, A., Siegel, R., Xu, J. & Ward, E. Cancer statistics, 2010. CA Cancer J.Clin. 60, P. 277–300 (2010).83.Jiang Y.P. Expression of chemokine CXCL12 and its receptor CXCR4 in humanepithelial ovarian cancer: an independent prognostic factor for tumor progression/ Y.P.
Jiang, X.H. Wu, B. Shi, W.X. Wu, G.R. Yin // Gynecol. Oncol. – 2006. –V. 103(1). – P. 226–233.84.Josefowicz S.Z. Regulatory T cells: mechanisms of differentiation and function /S.Z. Josefowicz, L-F. Lu, A.Y. Rudensky // Annu Rev Immunol. – 2012. – V. 30.– P. 531–564.85.Jung S.J. Correlation between Chemokine Receptor CXCR4 Expression andPrognostic Factors in Patients with Prostate Cancer / S.J. Jung, C.I. Kim, C.H.Park, H.S. Chang, B.H.
Kim, M.S. Choi, H.R. Jung // Korean J Urol. – 2011. –V. 52(9). – P. 607–611.86.Kadowaki N. Distinct CpG DNA and polyinosinic-polycytidylic acid doublestranded RNA, respectively, stimulate CD11c- type 2 dendritic cell precursorsand CD11c+ dendritic cells to produce type I IFN / N. Kadowaki, S. Antonenko,Y.J. Liu // J Immunol. – 2001. – V. 166. – P.
2291–2295.87.Kai H. CCR10 and CCL27 are overexpressed in cutaneous squamous cellcarcinoma / H. Kai, T. Kadono, T. Kakinuma, M. Tomita, H. Ohmatsu et al. //Pathol. Res. Pract. – 2011. – V. 207(1). – P. 43–48.88.Kaifi J.T. Tumor-cell homing to lymph nodes and bone marrow and CXCR4expression in esophageal cancer / J.T. Kaifi, E.F. Yekebas, P. Schurr, D. Obonyo,R.
Wachowiak et al. // J. Natl. Cancer Inst. – 2005. – V. 97(24). – P. 1840–1847.89.Kajiyama H. Involvement of SDF-1alpha/CXCR4 axis in the enhanced peritonealmetastasis of epithelial ovarian carcinoma / H. Kajiyama, K. Shibata, M.Terauchi, K. Ino, A. Nawa, F. Kikkawa // Int. J. Cancer. – 2008. – V. 122(1). – P.91–99.9190.Kang H. The elevated level of CXCR4 is correlated with nodal metastasis ofhuman breast cancer / H. Kang, G. Watkins, A. Douglas-Jones, R.E. Mansel,W.G.
Jiang // The Breast. – 2005. – V. 14. – P. 360–367.91.Karin M. NF-kappaB and cancer: mechanisms and targets / M. Karin // MolCarcinog. – 2006. – V. 45. – P. 355–361.92.Kawada K. Pivotal role of CXCR3 in melanoma cell metastasis to lymph nodes /K. Kawada, M. Sonoshita, H. Sakashita, A. Takabayashi, Y. Yamaoka et al. //Cancer Res. – 2004. – V. 64(11). – P.
4010–4017.93.Kiefer F. The role of chemokines and their receptors in angiogenesis / F. Kiefer,A.F. Siekmann // Cellular and molecular life sciences: CMLS. – 2011. – V.68(17). – P. 2811–2830.94.Kim J. Chemokine receptor CXCR4 expression in patients with melanoma andcolorectal cancer liver metastases and the association with disease outcome / J.Kim, T. Mori, S.L. Chen, F.F.
Amersi, S.R. Martinez et al. // Ann. Surg. – 2006.– V. 244(1). – P. 113–120.95.Kim S. Carcinoma-produced factors activate myeloid cells through TLR2 tostimulate metastasis / S. Kim et al. // Nature. – 2009. – V. 457. – P. 102–106.96.Klages K. Selective depletion of Foxp3+ regulatory T cells improves effectivetherapeutic vaccination against established melanoma / K. Klages, C.T.
![](https://s.studizba.com/z.php?f=/templates/si/i/noavatar.png&w=100&h=100&t=1"){kind=avatar}
